Achilles Therapeutics plc

NasdaqGS:ACHL 株式レポート

時価総額:US$41.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Achilles Therapeutics マネジメント

マネジメント 基準チェック /24

Achilles Therapeutics'の CEO はIraj Aliで、 Jan2018年に任命され、 の在任期間は 6.42年です。 の年間総報酬は$ 1.70Mで、 27.3%給与と72.7%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の2.71%を直接所有しており、その価値は$ 995.47K 。経営陣と取締役会の平均在任期間はそれぞれ6.4年と4.1年です。

主要情報

Iraj Ali

最高経営責任者

US$1.7m

報酬総額

CEO給与比率27.3%
CEO在任期間6.8yrs
CEOの所有権2.7%
経営陣の平均在職期間6.8yrs
取締役会の平均在任期間4.4yrs

経営陣の近況

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

CEO報酬分析

Achilles Therapeutics の収益と比較して、Iraj Ali の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$2mUS$463k

-US$70m

報酬と市場: Irajの 総報酬 ($USD 1.70M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Irajの報酬と会社の業績を比較するにはデータが不十分です。


CEO(最高経営責任者

Iraj Ali (49 yo)

6.8yrs

在職期間

US$1,698,000

報酬

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Iraj Ali
CEO & Director6.8yrsUS$1.70m2.71%
$ 1.1m
Karl Peggs
Founder & Chief Medical Officerno dataデータなし1.36%
$ 571.3k
Sergio Quezada
Founder & Chief Scientific Officer8.8yrsデータなし1.12%
$ 471.1k
Robert Coutts
Chief Financial Officer3.9yrsデータなし0.66%
$ 275.0k
Mark Lowdell
Founder8.8yrsデータなしデータなし
Charles Swanton
Founder8.8yrsデータなしデータなし
Lee Stern
Vice President of Investor Relations & External Communications3.8yrsデータなしデータなし
Daniel Carey Hood
General Counsel & Company Secretary1.9yrsデータなしデータなし
Julia Wilson
Head of Communicationsno dataデータなしデータなし
Tariq Ahmed
Executive Vice President of Peopleno dataデータなしデータなし
Edward Samuel
Executive Vice President of Technical Operationsno dataデータなしデータなし
Shree Patel
Executive Vice President of Supply Operationsno dataデータなしデータなし

6.8yrs

平均在職期間

50.5yo

平均年齢

経験豊富な経営陣: ACHLの経営陣は経験豊富で経験豊富です(平均在職期間は6.4年)。


取締役

名称ポジション在職期間報酬所有権
Iraj Ali
CEO & Director8.6yrsUS$1.70m2.71%
$ 1.1m
Edwin Moses
Independent Chairman of the Board5.8yrsUS$379.00k0.55%
$ 230.8k
Carsten Boess
Independent Non-Executive Director4.5yrsUS$176.00k0%
$ 0
Bernhard R. Ehmer
Non-Executive Director2.5yrsUS$106.00k0%
$ 0
Markwin Velders
Member of Scientific Advisory Board3.4yrsデータなしデータなし
Scott Antonia
Member of Scientific Advisory Board4.4yrsデータなしデータなし
Cassian Yee
Member of Scientific Advisory Board2.8yrsデータなしデータなし
Michael Giordano
Independent Non-Executive Director6.1yrsUS$189.00k0.11%
$ 47.6k
Elizabeth Jaffee
Member of Scientific Advisory Board4.4yrsデータなしデータなし
Christopher Klebanoff
Member of Scientific Advisory Board4.4yrsデータなしデータなし
Alena Gros
Member of Scientific Advisory Board2.7yrsデータなしデータなし
Ben Creelan
Member of Scientific Advisory Board2.7yrsデータなしデータなし

4.4yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: ACHLの 取締役会経験豊富 であると考えられます ( 4.1年の平均在任期間)。